These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38074069)

  • 1. Radioimmunotherapy With WT1 Dendritic Cell Vaccine for End-Stage Lung Adenocarcinoma Markedly Shrinks Tumors.
    Nagai H; Karube R; Zhao F
    Cureus; 2023 Nov; 15(11):e48412. PubMed ID: 38074069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WT1 Dendritic Cell Vaccine Therapy Improves Immune Profile and Prolongs Progression-Free Survival in End-Stage Lung Cancer.
    Nagai H; Karube R
    Cureus; 2023 Oct; 15(10):e47320. PubMed ID: 38022278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Radiation Therapy, Wim's Tumor 1 (WT1) Dendritic Cell Vaccine Therapy, and α-Galactosylceramide-Pulsed Dendritic Cell Vaccine Therapy for End-Stage Small Bowel Cancer.
    Nagai H; Chen H; Karube R; Koitabashi Y; Numata O; Yamahara K
    Cureus; 2024 Jul; 16(7):e64972. PubMed ID: 39035592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
    Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
    Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines.
    Hanada S; Tsuruta T; Haraguchi K; Okamoto M; Sugiyama H; Koido S
    Hum Vaccin Immunother; 2019; 15(2):397-406. PubMed ID: 30230959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review.
    Hashii Y; Oka Y; Kagawa N; Hashimoto N; Saitou H; Fukuya S; Kanegae M; Ikejima S; Oji Y; Ozono K; Tsuboi A; Sugiyama H
    Front Oncol; 2020; 10():1188. PubMed ID: 32793489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late-Stage Ovarian Cancer With Systemic Multiple Metastases Shows Marked Shrinkage Using a Combination of Wilms' Tumor Antigen 1 (WT1) Dendritic Cell Vaccine, Natural Killer (NK) Cell Therapy, and Nivolumab.
    Nagai H; Karube R
    Cureus; 2024 Mar; 16(3):e56685. PubMed ID: 38523872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1.
    Ito Z; Kan S; Bito T; Horiuchi S; Akasu T; Yoshida S; Kajihara M; Hokari A; Saruta M; Yoshida N; Kobayashi M; Ohkusa T; Shimodaira S; Okamoto M; Sugiyama H; Koido S
    Oncology; 2019; 97(3):135-148. PubMed ID: 31216557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients.
    Liu Q; Lou Y; Li L; Yang G; Cui H; Cheng Z; Li Y; Liu M; Deng C; Wan D; Yan Y; Jia L
    Integr Cancer Ther; 2022; 21():15347354221083968. PubMed ID: 35313775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
    Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
    Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model.
    Hu Y; Paris S; Barsoumian H; Abana CO; He K; Sezen D; Wasley M; Masrorpour F; Chen D; Yang L; Dunn JD; Gandhi S; Nguyen QN; Cortez MA; Welsh JW
    J Nanobiotechnology; 2021 Dec; 19(1):416. PubMed ID: 34895262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palliative Chemotherapy: Does It Only Provide False Hope? The Role of Palliative Care in a Young Patient With Newly Diagnosed Metastatic Adenocarcinoma.
    Doverspike L; Kurtz S; Selvaggi K
    J Adv Pract Oncol; 2017; 8(4):382-386. PubMed ID: 30018843
    [No Abstract]   [Full Text] [Related]  

  • 16. Radiation and resolve: unlocking the synergistic potential of radioimmunotherapy in advanced lung cancer management.
    Zhang Y; Li Z; Zou B
    Immunotherapy; 2024 Feb; 16(2):55-58. PubMed ID: 38054261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for patients with non-small cell lung cancer who could survive long term chemotherapy.
    Wu XY; Huang XE
    Asian Pac J Cancer Prev; 2015; 16(2):647-52. PubMed ID: 25684501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
    Bozorgmehr F; Chung I; Christopoulos P; Krisam J; Schneider MA; Brückner L; Mueller DW; Thomas M; Rieken S
    BMC Cancer; 2020 Aug; 20(1):806. PubMed ID: 32842974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
    Farzad M; De Luca MC; Rubino G; Pirtoli L; Pepi F; Sebaste L; Ponticelli P; Atzeni G; Maranzano E; Silvano G
    Radiol Med; 2001; 102(1-2):72-7. PubMed ID: 11677442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.